Mirxes launches HK$1.08b Hong Kong IPO

The group is selling 46.62 million shares.

Singapore biotech firm Mirxes has launched its initial public offering in Hong Kong, seeking to raise $180m (HK$1.08b.)

The group is selling 46.62 million shares, 41,958,000 of the IPO offer will be available to international investors, whilst 4,662,000 shares are available to public subscription in Hong Kong.

“We estimate that we will receive net proceeds of approximately HK$887.6m after deducting the underwriting fees and expenses payable by us in the Global Offering, at the Offer Price of HK$23.30 per Offer Share,” the group said in its bourse filing to the HKEX.

Follow the link for more news on

MiRXES

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia